Cigna shares trade 28% below value with strong growth and dividend potential through 2031

Cigna Group remains a strong buy with shares trading 28% below their fair value, supported by double-digit adjusted EPS growth. Key growth drivers include the Accredo and AI-powered Pharmacy Forward platforms, which are expected to boost revenue and margins through 2028. The company holds a solid A- credit rating, generates strong free cash flow, and offers a secure, growing dividend with low payout ratios. Cigna is projected to deliver mid-teens annual total returns through 2031, driven by consistent earnings beats and disciplined capital management.